Skip to main content
Premium Trial:

Request an Annual Quote

DermTech Inks Coverage Deal for Melanoma Assay

NEW YORK (GenomeWeb) – DermTech announced on Monday that it has secured payor coverage for its pigmented lesion assay (PLA) from CareFirst Blue Cross/Blue Shield and its affiliate CareFirst BlueChoice.

The non-invasive assay is designed to analyze the expression of two oncogenes to differentiate malignant melanoma from benign pigmented skin lesions. DermTech said that CareFirst will now cover the test for its 3.4 million members, effective for claims for services performed on or after June 1.

"This is the first contract of the many anticipated for our skin cancer pathology tests executed directly with one of the larger BlueCross Blue/Shield providers," Sarah Dion, vice president of sales and marketing at DermTech, said in a statement. 

About a year ago, DermTech signed an agreement under which Quest Diagnostics-owned dermatopathology services provider Dermpath is helping market the PLA.